Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Sjogren's Syndrome 1Scleroderma, Systemic 1Psoriasis 1Oropharyngeal Neoplasms 1Multiple Sclerosis 1Lupus Erythematosus, Systemic 1Inflammatory Bowel Diseases 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Dermatomyositis 1Crohn Disease 1Colitis, Ulcerative 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Arthritis, Psoriatic 1

Interventions

cabozantinib 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Platinum Compounds 1Nivolumab 1Methods 1Ipilimumab 1Interviews as Topic 1Educational Status 1Early Intervention, Educational 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Crohn Disease × Platinum Compounds × 30 days × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡